Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001479290-24-000128
Filing Date
2024-11-07
Accepted
2024-11-07 16:16:37
Documents
88
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rvnc-20240930.htm   iXBRL 10-Q 1600233
2 EX-10.1 rvncq324exhibit101.htm EX-10.1 29643
3 EX-10.2 rvncq324exhibit102.htm EX-10.2 24203
4 EX-31.1 rvncq324exhibit311.htm EX-31.1 8708
5 EX-31.2 rvncq324exhibit312.htm EX-31.2 8706
6 EX-32.1 rvncq324exhibit321.htm EX-32.1 5103
7 EX-32.2 rvncq324exhibit322.htm EX-32.2 5141
  Complete submission text file 0001479290-24-000128.txt   8934422

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20240930.xsd EX-101.SCH 61292
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20240930_cal.xml EX-101.CAL 116377
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20240930_def.xml EX-101.DEF 306874
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20240930_lab.xml EX-101.LAB 749982
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20240930_pre.xml EX-101.PRE 531904
91 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20240930_htm.xml XML 1374829
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36297 | Film No.: 241436020
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)